Nephrol Dial Transplant (2004) 19: 391-399
© ERA–EDTA 2004; all rights reserved
Original Article
The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure
1Cardiology Division, Center for Education and Research in Therapeutics, and Center for Health Services Research, Vanderbilt University and Geriatric Research, Education and Clinical Center, Nashville VAMC, Nashville, TN, 2Case Western Reserve University, 3Department of Emergency Medicine and 6Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, 4The Ohio State University, Columbus, OH and 5Department of Medicine, Nephrology Division and Renal Transplant Service, University of California, San Francisco, CA, USA
Correspondence and reprint requests to: Javed Butler MD, Cardiology Division, 383 PRB, Vanderbilt University Medical Center, Nashville, TN 37232-6300, USA. Email: javed.butler{at}vanderbilt.edu
Background. Nesiritide (B-type natriuretic peptide) reduces preload and afterload, and causes natriuresis, diuresis and suppression of norepinephrine, endothelin-1 and aldosterone. In this study, we sought to explore the safety and efficacy of nesiritide in patients with acute congestive heart failure (CHF) and renal insufficiency (RI).
Methods. We studied the effects of nesiritide in patients with RI in the VMAC trial database, a multi-centre, randomized controlled trial (n = 489) of patients with acute decompensated CHF.
Results. The mean serum creatinine (SCr) in nesiritide-treated patients with RI (SCr 
2.0 mg/dl, n = 60, range 2.0–11.1 mg/dl) and without RI (SCr < 2.0 mg/dl, n = 209) was 3.0±1.51 and 1.2±0.34 mg/dl, respectively. Pulmonary capillary wedge pressure (PCWP) was reduced significantly and similarly in both RI and no RI groups starting at 15 min into nesiritide infusion from a baseline of 29.9±8.1 and 26.6±6.0 mmHg, respectively. Addition of placebo to standard therapies yielded no further improvement in PCWP in patients with RI; in contrast, nesiritide significantly reduced PCWP at every time point during 24 h. The effects of nitroglycerin were less robust than those of nesiritide, and PCWP was not significantly reduced by nitroglycerin at the 3 h primary end-point. At 24 h, 83% of the RI patients and 91% of patients without RI treated with nesiritide reported improvements in dyspnoea. Nesiritide was well tolerated in patients with RI and no RI, and renal function was preserved in both groups.
Conclusions. In patients with RI, nesiritide was safe and improved haemodynamics and dyspnoea.
Keywords: brain natriuretic peptide; B-type natriuretic peptide; chronic kidney disease; haemodynamics; heart failure; nesiritide; renal insufficiency
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Arora, K. Clarke, V. Srinivasan, and A. Gradman Effect of nesiritide on renal function in patients admitted for decompensated heart failure QJM, November 1, 2007; 100(11): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Mentzer Jr, M. C. Oz, R. N. Sladen, A. H. Graeve, R. F. Hebeler Jr, J. M. Luber Jr, N. G. Smedira, and on behalf of the NAPA Investigators Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial J. Am. Coll. Cardiol., February 13, 2007; 49(6): 716 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Abraham, K. F. Adams, G. C. Fonarow, M. R. Costanzo, R. L. Berkowitz, T. H. LeJemtel, M. L. Cheng, J. Wynne, the ADHERE Scientific Advisory Committee Investiga, and and the ADHERE Study Group In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications: An Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE) J. Am. Coll. Cardiol., July 5, 2005; 46(1): 57 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Stevenson, A. Nohria, and L. Mielniczuk Torrent or Torment From the Tubules?: Challenge of the Cardiorenal Connections J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2004 - 2007. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Burnett Nesiritide: new hope for acute heart failure syndromes? Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B25 - B30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Shlipak and B. M. Massie The Clinical Challenge of Cardiorenal Syndrome Circulation, September 21, 2004; 110(12): 1514 - 1517. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, K. Rao, et al. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine Circulation, September 21, 2004; 110(12): 1620 - 1625. [Abstract] [Full Text] [PDF]
|
|